Want to see CH:KURN full AI Analyst Report?
Total Valuation
Kuros Biosciences has a market cap or net worth of CHF848.98M. The enterprise value is CHF764.71.
Market CapCHF848.98M
Enterprise ValueCHF764.71
Share Statistics
Kuros Biosciences has 39,671,734 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding39,671,734
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kuros Biosciences’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 4.80%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)4.80%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee681.46K
Profits Per Employee28.67K
Employee Count178
Asset Turnover1.13
Inventory Turnover0.98
Valuation Ratios
The current PE Ratio of Kuros Biosciences is 118.2. Kuros Biosciences’s PEG ratio is -3.21.
PE Ratio118.2
PS Ratio8.71
PB Ratio15.78
Price to Fair Value15.78
Price to FCF-439.50
Price to Operating Cash Flow-2.93K
PEG Ratio-3.21
Income Statement
In the last 12 months, Kuros Biosciences had revenue of 121.30M and earned 2.12M in profits. Earnings per share was 0.06.
Revenue121.30M
Gross Profit104.79M
Operating Income7.33M
Pretax Income4.16M
Net Income2.12M
EBITDA10.13M
Earnings Per Share (EPS)0.06
Cash Flow
In the last 12 months, operating cash flow was -292.91K and capital expenditures -6.32M, giving a free cash flow of -6.61M billion.
Operating Cash Flow-292.91K
Free Cash Flow-6.61M
Free Cash Flow per Share-0.17
Dividends & Yields
Kuros Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.43
52-Week Price Change-21.73%
50-Day Moving Average20.71
200-Day Moving Average24.25
Relative Strength Index (RSI)49.59
Average Volume (3m)128.87K
Important Dates
Kuros Biosciences upcoming earnings date is Mar 17, 2027, TBA (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateMar 17, 2027
Ex-Dividend Date―
Financial Position
Kuros Biosciences as a current ratio of 1.96, with Debt / Equity ratio of 15.29%
Current Ratio1.96
Quick Ratio1.45
Debt to Market Cap<0.01
Net Debt to EBITDA-1.16
Interest Coverage Ratio24.04
Taxes
In the past 12 months, Kuros Biosciences has paid 2.12M in taxes.
Income Tax2.12M
Effective Tax Rate0.51
Enterprise Valuation
Kuros Biosciences EV to EBITDA ratio is 103.14, with an EV/FCF ratio of -434.62.
EV to Sales8.61
EV to EBITDA103.14
EV to Free Cash Flow-434.62
EV to Operating Cash Flow-2.76K
Balance Sheet
Kuros Biosciences has CHF7.85M in cash and marketable securities with CHF11.01M in debt, giving a net cash position of -CHF3.16M billion.
Cash & Marketable SecuritiesCHF7.85M
Total DebtCHF11.01M
Net Cash-CHF3.16M
Net Cash Per Share-CHF0.08
Tangible Book Value Per ShareCHF0.90
Margins
Gross margin is 85.28%, with operating margin of 6.04%, and net profit margin of 1.75%.
Gross Margin85.28%
Operating Margin6.04%
Pretax Margin3.43%
Net Profit Margin1.75%
EBITDA Margin8.35%
EBIT Margin6.04%
Analyst Forecast
The average price target for Kuros Biosciences is CHF32.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF32.50
Price Target Upside64.14% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast40.91%
EPS Growth Forecast―